Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168109922> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3168109922 endingPage "12069" @default.
- W3168109922 startingPage "12069" @default.
- W3168109922 abstract "12069 Background: Increased life expectancy for cancer survivors following advances in treatment has led to a greater likelihood of developing long-term complications. Among them is chemotherapy-induced peripheral neuropathy (CIPN), which adversely impacts the functional capacity of survivors. We assessed prevalence and predictors of CIPN in a cohort of African-American (AA) cancer survivors. Methods: The study population included 633 breast, colorectal, prostate and lung cancer survivors who received chemotherapy and participated in the Detroit Research on Cancer Survivorship (ROCS) study. Presence of CIPN was based on self-reported pain, numbness or tingling in the hands or feet, occurring either for the first time or worsening after chemotherapy. If participants reported continued CIPN at the time of survey, their symptoms were reported as persistent. CIPN severity was self-reported as mild, moderate or severe. Logistic regression analysis was used to evaluate socio-demographic and clinical factors (including 12 common comorbid conditions) associated with CIPN prevalence, persistence and severity. Results: Overall, 67% of the cohort reported CIPN at a mean time of 25.3 months (range 2-74 months) after cancer diagnosis, and 51% reported persistent CIPN. The distribution of CIPN severity consisted of 32.2% with mild, 30.8% with moderate, and 36.9% with moderate to severe symptoms. Diagnosis of primary breast (OR 3.99, 95% CI 1.52-10.46) or colorectal cancers (OR 5.24, 95% CI 2.17-12.69) conferred greater CIPN prevalence relative to a diagnosis of prostate cancer. The presence of each additional comorbid condition among those outlined in the survey also conferred a 20% greater prevalence of CIPN (OR 1.2, 95% CI 1.03-1.39). Similar trends were seen among those who reported persistent CIPN. Using age > 65 at diagnosis as the reference group, age < 50 (OR 2.64, 95% CI 1.43-4.88) and age 51-64 (OR 1.96, 95% CI 1.14-3.35) resulted in an increased risk of moderate or severe compared to mild CIPN. Conclusions: In the Detroit ROCS cohort, CIPN was reported in two-thirds of cancer survivors receiving chemotherapy. Out of them, more than one-third reported moderate to severe symptoms, more commonly seen among those age < 65. Consideration of CIPN as a prominent long-term complication of cancer treatment should play a role in treatment decisions and development of new chemotherapy regimens." @default.
- W3168109922 created "2021-06-22" @default.
- W3168109922 creator A5000445673 @default.
- W3168109922 creator A5002190901 @default.
- W3168109922 creator A5002793047 @default.
- W3168109922 creator A5012884793 @default.
- W3168109922 creator A5013481732 @default.
- W3168109922 creator A5013768762 @default.
- W3168109922 creator A5017481000 @default.
- W3168109922 creator A5024100091 @default.
- W3168109922 creator A5074989278 @default.
- W3168109922 date "2021-05-20" @default.
- W3168109922 modified "2023-10-16" @default.
- W3168109922 title "Prevalence and predictors of peripheral neuropathy after chemotherapy: Outcomes from the Detroit Research on Cancer Survivorship (ROCS) cohort." @default.
- W3168109922 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.12069" @default.
- W3168109922 hasPublicationYear "2021" @default.
- W3168109922 type Work @default.
- W3168109922 sameAs 3168109922 @default.
- W3168109922 citedByCount "0" @default.
- W3168109922 crossrefType "journal-article" @default.
- W3168109922 hasAuthorship W3168109922A5000445673 @default.
- W3168109922 hasAuthorship W3168109922A5002190901 @default.
- W3168109922 hasAuthorship W3168109922A5002793047 @default.
- W3168109922 hasAuthorship W3168109922A5012884793 @default.
- W3168109922 hasAuthorship W3168109922A5013481732 @default.
- W3168109922 hasAuthorship W3168109922A5013768762 @default.
- W3168109922 hasAuthorship W3168109922A5017481000 @default.
- W3168109922 hasAuthorship W3168109922A5024100091 @default.
- W3168109922 hasAuthorship W3168109922A5074989278 @default.
- W3168109922 hasConcept C121608353 @default.
- W3168109922 hasConcept C126322002 @default.
- W3168109922 hasConcept C134018914 @default.
- W3168109922 hasConcept C143998085 @default.
- W3168109922 hasConcept C151956035 @default.
- W3168109922 hasConcept C172400760 @default.
- W3168109922 hasConcept C1862650 @default.
- W3168109922 hasConcept C201903717 @default.
- W3168109922 hasConcept C2779289229 @default.
- W3168109922 hasConcept C2779901536 @default.
- W3168109922 hasConcept C2780192828 @default.
- W3168109922 hasConcept C2908647359 @default.
- W3168109922 hasConcept C526805850 @default.
- W3168109922 hasConcept C530470458 @default.
- W3168109922 hasConcept C555293320 @default.
- W3168109922 hasConcept C71924100 @default.
- W3168109922 hasConcept C72563966 @default.
- W3168109922 hasConcept C99454951 @default.
- W3168109922 hasConceptScore W3168109922C121608353 @default.
- W3168109922 hasConceptScore W3168109922C126322002 @default.
- W3168109922 hasConceptScore W3168109922C134018914 @default.
- W3168109922 hasConceptScore W3168109922C143998085 @default.
- W3168109922 hasConceptScore W3168109922C151956035 @default.
- W3168109922 hasConceptScore W3168109922C172400760 @default.
- W3168109922 hasConceptScore W3168109922C1862650 @default.
- W3168109922 hasConceptScore W3168109922C201903717 @default.
- W3168109922 hasConceptScore W3168109922C2779289229 @default.
- W3168109922 hasConceptScore W3168109922C2779901536 @default.
- W3168109922 hasConceptScore W3168109922C2780192828 @default.
- W3168109922 hasConceptScore W3168109922C2908647359 @default.
- W3168109922 hasConceptScore W3168109922C526805850 @default.
- W3168109922 hasConceptScore W3168109922C530470458 @default.
- W3168109922 hasConceptScore W3168109922C555293320 @default.
- W3168109922 hasConceptScore W3168109922C71924100 @default.
- W3168109922 hasConceptScore W3168109922C72563966 @default.
- W3168109922 hasConceptScore W3168109922C99454951 @default.
- W3168109922 hasIssue "15_suppl" @default.
- W3168109922 hasLocation W31681099221 @default.
- W3168109922 hasOpenAccess W3168109922 @default.
- W3168109922 hasPrimaryLocation W31681099221 @default.
- W3168109922 hasRelatedWork W1874292799 @default.
- W3168109922 hasRelatedWork W1981542504 @default.
- W3168109922 hasRelatedWork W2081740839 @default.
- W3168109922 hasRelatedWork W2104568311 @default.
- W3168109922 hasRelatedWork W2245189862 @default.
- W3168109922 hasRelatedWork W2890859100 @default.
- W3168109922 hasRelatedWork W2999207890 @default.
- W3168109922 hasRelatedWork W3112166790 @default.
- W3168109922 hasRelatedWork W377899687 @default.
- W3168109922 hasRelatedWork W4226116328 @default.
- W3168109922 hasVolume "39" @default.
- W3168109922 isParatext "false" @default.
- W3168109922 isRetracted "false" @default.
- W3168109922 magId "3168109922" @default.
- W3168109922 workType "article" @default.